|
注册号: Registration number: |
ChiCTR2600127132 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-25 11:33:17 |
|
注册时间: Date of Registration: |
2026-06-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
通过腹腔镜胆囊切除术预防特发性急性胰腺炎复发(PICUS-2):一项多中心随机试验 |
|
Public title: |
Preventing recurrent 'idiopathic' acute pancreatitis through laparoscopic cholecystectomy (PICUS-2): a multicenter randomized trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
通过腹腔镜胆囊切除术预防特发性急性胰腺炎复发(PICUS-2):一项多中心随机试验 |
|
Scientific title: |
Preventing recurrent 'idiopathic' acute pancreatitis through laparoscopic cholecystectomy (PICUS-2): a multicenter randomized trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
毛恩强 |
研究负责人: |
毛恩强 |
|
Applicant: |
Enqiang Mao |
Study leader: |
Enqiang Mao |
|
申请注册联系人电话: Applicant telephone: |
+86 21 64370045 |
研究负责人电话:
Study leader's |
+86 21 34187604 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
maoeq@yeah.net |
研究负责人电子邮件: Study leader's E-mail: |
maoeq@yeah.net |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市黄浦区瑞金二路197号 |
研究负责人通讯地址: |
上海市瑞金二路197号 |
|
Applicant address: |
No. 197, Ruijin 2nd Road, Huangpu District, Shanghai, China |
Study leader's address: |
No. 197, Ruijin 2nd Road, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属瑞金医院 |
||
|
Applicant's institution: |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China |
||
|
研究负责人所在单位: |
上海交通大学医学院附属瑞金医院 |
||
|
Affiliation of the Leader: |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2026)临伦审第(408)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属瑞金医院涉及人体的临床与科研项目伦理委员会 |
||
|
Name of the ethic committee: |
Ruijin Hospital Ethics Committee, Shanghai JiaoTong University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-06-04 00:00:00 | ||
|
伦理委员会联系人: |
赵彦琳 |
||
|
Contact Name of the ethic committee: |
Zhao YanLin |
||
|
伦理委员会联系地址: |
上海市瑞金二路197号 |
||
|
Contact Address of the ethic committee: |
No. 197, Ruijin 2nd Road, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 80585870 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zyl02d86@rjh.com.cn |
|
研究实施负责(组长)单位: |
上海交通大学医学院附属瑞金医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市瑞金二路197号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 197, Ruijin 2nd Road, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised |
||||||||||||||||||||||
|
研究疾病: |
腹痛 |
||||||||||||||||||||||
|
Target disease: |
Abdominal pain |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
主要目的:确定腹腔镜胆囊切除术(LC)在首次、第二次或第三次发作的急性特发性胰腺炎患者中预防急性胰腺炎复发的有效性。 次要目的:确定胆道事件的发生情况、LC相关并发症的出现率、胰腺炎复发次数及严重程度、生活质量(QALY)、成本(医院和社会成本)以及成本效益比。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary Objective: To determine the efficacy of LC in patients after a first, second or third episode of acute pancreatitis (which is idiopathic) in the prevention of recurrent acute pancreatitis. Secondary Objective: To determine the occurrence of biliary events, complications of LC, number, and severity of recurrent episodes of pancreatitis, quality of life (QALY), costs (hospital and societal) and cost-effectiveness. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.发作超过3次的急性特发性胰腺炎患者; 2.慢性胰腺炎的诊断; 3.坏死性胰腺炎的诊断; 4.当前患有胰腺恶性肿瘤或主胰管型导管内乳头状黏液性肿瘤; 5.既往接受过胆囊切除术; 6.已明确病因的急性胰腺炎; 7.无法完成包括超声内镜在内的完整诊断检查的患者; 8.有胰腺分裂症病史; 9.处于怀孕或哺乳期。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with more than 3 episodes of idiopathic acute pancreatitis; 2. Diagnosis of chronic pancreatitis; 3. Diagnosis of necrotizing pancreatitis; 4. Current pancreatic malignancy or main-duct IPMN; 5. Prior cholecystectomy; 6. Documented etiology of acute pancreatitis; 7. Patients in whom complete diagnostic work-up including EUS is not possible (e.g. Roux-and-Y bypass); 8. History of pancreas divisum# #Imaging to rule out pancreas divisum not required; 9. Pregnant or breastfeeding. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-30 00:00:00至 To 2029-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-07-01 00:00:00 至 To 2028-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由荷兰胰腺炎研究组(DPSG)数据中心的独立统计人员使用计算机生成的随机化序列(Castor EDC系统,阿姆斯特丹) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Generated by an independent statistician from the Dutch Pancreatitis Study Group (DPSG) data center using a computer-generated randomization sequence (Castor EDC, Amsterdam) |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签,对评估者设盲 |
|
Blinding: |
Open-label study with blinded-evaluators |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
编码后的数据将安全存储在荷兰胰腺炎研究组(DPSG)数据中心,仅限DPSG研究组成员访问。原始数据将在主要研究结果发表后(预计2030年)根据合理请求共享。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Encoded data will be securely stored at the DPSG (Dutch Pancreatitis Study Group) data center, accessible only to DPSG research team members. Individual participant data will be shared upon reasonable request after publication of primary results (expected in 2030). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表:采用纸质版及电子版CRF,记录患者基线特征、实验室检查、影像学结果、手术信息、随访数据、不良事件及问卷结果。所有CRF需经研究者签名确认。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF: Paper and electronic Case Record Forms will be used to document baseline characteristics, laboratory tests, imaging results, surgical information, follow-up data, adverse events, and questionnaire results. All CRFs must be signed and confirmed by the investigator. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |